Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
11.20
-0.05
(-0.44%)
At close: February 26 at 9:50:08 PM GMT+1
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Bruno Wohlschlegel | CEO & Chairman of Management Board | 180.96k | -- | 1968 |
| Mr. Thomas Milz | Chief Product Officer & Deputy Chairman of Management Board | 324k | -- | -- |
| Mr. Thomas Zimmermann | CFO & Member of Management Board | -- | -- | -- |
| Mr. Harald Weyand | Head of Marketing | -- | -- | -- |
| Ms. Susanne Böhm | Head of HR | -- | -- | -- |
| Dr. Olaf Randerath | Head of Medicine | -- | -- | -- |
| Dr. Susanne Endreß | Head of QA, Drug Safety & Regulatory Affairs | -- | -- | -- |
Apontis Pharma AG
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 177
Description
Apontis Pharma AG engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany. It offers single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prophylaxis, as well as respiratory diseases and diabetes. The company was founded in 1946 and is based in Monheim am Rhein, Germany. As of November 21, 2024, Apontis Pharma AG operates as a subsidiary of Zentiva AG.
Corporate Governance
Apontis Pharma AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
March 26, 2025 at 10:59 AM UTC - March 31, 2025 at 12:00 PM UTC
Apontis Pharma AG Earnings Date
Recent Events
Recent Events Information Not Available